Srkalovic, G., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Nazemzadeh, R., Cannon, T. L., … Schilsky, R. L. (2022). Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Srkalovic, Gordan, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Reza Nazemzadeh, Timothy Lewis Cannon, Herbert Leon Duvivier, et al. “Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Nazemzadeh R, Cannon TL, et al. Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Srkalovic, Gordan, et al. “Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Nazemzadeh R, Cannon TL, Duvivier HL, Yost KJ, Pakkala S, Alva AS, Behl D, Gold PJ, Calfa CJ, Ngirailemesang M, Powell SF, O’Lone R, Grantham GN, Halabi S, Schilsky RL. Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JOURNAL OF CLINICAL ONCOLOGY. 2022.